Drug Trial Radar · NCT01221597
Study of AA4500 in the Treatment of Peyronie's Disease
Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
418
Actual
Start
Sep 2010
Primary completion
Apr 2012
Study completion Apr 2012
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle. Before dosing, subjects will be stratified by degree of penile curvature deformity (ie, 30º to 60º or 61º to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo. In this study, qualified subjects may receive up to four treatment cycles; each cycle will be separated by a period of 42 days (± 5 days). During each treatment cycle, subjects will receive two injections of study drug with at least 24 hours but not more than 72 hours between injections. After the final injection of each treatment cycle, the investigator or qualified designee will model the penile plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15 degrees after the first, second, or third cycle of injections or if further treatment is not clinically indicated, subsequent treatment cycles will not be administered. Following the maximum of four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 169 (± 7 days), 232 (± 7 days), 295 (± 7 days), 365 (± 7 days) (nominal weeks 24, 33, 42 and 52). Subjects randomized to placebo may receive open-label AA4500 treatment after completing this study as part of another protocol.
Conditions
- Peyronie's Disease
Interventions
AA4500Biological
2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
PlaceboBiological
2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Penile CurvatureTime frame: Baseline and Week 52
- Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)Time frame: Baseline and Week 52
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Urology Centers of Alabama, PC
Homewood, Alabama
HOPE Research Institute, LLC
Phoenix, Arizona
Urology Associates Medical Group
Burbank, California
California Professional Research
Newport Beach, California
San Diego Sexual Medicine
San Diego, California
Grove Hill Clinical Research, Grove Hill Medical Center
New Britain, Connecticut
The Urology Center, PC
New Haven, Connecticut
DCT-Celebration, LLC dba Discovery Clinical Trials
Celebration, Florida
Palm Beach Urology Associates
Wellington, Florida
Southeastern Medical Research Institute
Columbus, Georgia
DuPage Medical Group
Downers Grove, Illinois
Urology of Indiana LLC
Avon, Indiana
Chesapeake Urology Research Associates
Baltimore, Maryland
Johns Hopkins Hospital
Baltimore, Maryland
Mens Health Boston
Brookline, Massachusetts
Mayo Clinic at Rochester, Dept. of Urology
Rochester, Minnesota
Center for Reproductive Medicine
Hackensack, New Jersey
Division of Urology at Maimonides Medical Center
Brooklyn, New York
Alliance Urology Specialists, PA
Greensboro, North Carolina
Wake Urological Associates
Raleigh, North Carolina
Tristate Urologic Services PSC Inc. dba TUG Research
Cincinnati, Ohio
Urology Health Specialists,LLC
Bryn Mawr, Pennsylvania
Urological Associates of Lancaster
Lancaster, Pennsylvania
Alpha Clinical Research, LLC
Clarksville, Tennessee
Urology Associates of North Texas
Arlington, Texas
Baylor College of Medicine, Department of Urology
Houston, Texas
Salt Lake Research, PLLC
Salt Lake City, Utah
Urology of Virginia - Sentara Medical Group
Norfolk, Virginia
Medical College of Wisconsin, Department of Urology
Milwaukee, Wisconsin
Australian Centre for Sexual Health
St Leonards, New South Wales, Australia
Western Urology
Westmead, New South Wales, Australia
AusTrials
Kipparing, Queensland, Australia
Repatriation General Hospital
Daws Park, South Australia, Australia
Australian Urology Associates Pty Ltd
Malvern, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.